New Hampshire: (603) 828-0100
New Patient Referrals: 1-833-826-6327

Below is a list of current clinical trials open to enrollment at New England Cancer Specialists. Trials can open and close very quickly, depending on the phase of the study, responses from patients already enrolled, or FDA requests.

We try to have a trial available in every disease area, but this isn’t always possible. If you don’t see a study that might be right for you, please ask your doctor or nurse.

For a full list of clinical trials across the U.S., visit ClinicalTrials.gov.

If you have questions or wish to speak with someone from our research department, contact us.

Breast

Breast, CB-1-21 (Checkmate 7FL)                                                                                      A Randomized, Multicenter, Double-blind, Placebo-controlled Phase 3 Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Patients With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer Learn more

Breast, EA1181 (CompassHER2-pCR)
Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response Part 1 Component of: The CompassHER2 Trials (Comprehensive Use of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer)

Breast, A011801 

The CompassHER2 Trials: CompassHER2 Residual Disease (RD), a Double-Blinded, Phase III Trial of T-DM1 Compared with T-DM1 and Tucatinib

Breast, CB-3-21 (MK3475-B49)

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Pembrolizumab Plus Chemotherapy vs. Placebo Plus Chemotherapy for the Treatment of Chemotherapy Candidate HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer Keynote B49 

Breast, N-1-21 (WO42633)

A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy ASTEFANIA

Genomics

Genomics, EAY131 (MATCH)
Molecular Analysis for Therapy Choice. Learn more

TAPUR: Targeted Agent and Profiling Utilization Registry Study

TAPISTRY: Tumor-Agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform Trial

 

Lung

Lung, (T-4-20) TH-138                                                                                                   A Phase II Randomized Trial of Carboplatin + Pemetrexed + Bevacizumab, With or Without Atezolizumab in Stage IV Non-squamous NSCLC Patients Who Harbor a Sensitizing EGFR Mutation or Have Never Smoked Learn more

Lung, ECOG E4512
A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein. Learn more

Lung, EV-2-19 (MRT516-005)
A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy in Combination with Checkpoint Inhibitor Therapy.

Lung, GO41854 Skyscraper03 (T-2-20)‚Äč
A Phase III, Open-label, Randomized Study of Atezolizumab and Tiragolumab Compared with Durvalumab in Patients with Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer who have not Progressed After Concurrent Platinum-based Chemoradiation

Melanoma

Melanoma, EA6141                                                                                                           A Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma Learn more

Melanoma, JPW-1-21 (MM 19-291)

A Phase I/II Study of Twice Weekly Ixazomib Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

 

Renal

Renal, T-4-21 (MK6482-012)

An Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab (MK3475) in Combination with Belzutifan (MK6482) and Lenvatinib (MK7902), or MK-1308A in Combination with Lenvatinib, versus Pembrolizumab and Lenvatinib, as First-line Treatment in Participants with Advanced Clear Cell Renal Cell Carcinoma (ccRCC)

NECS Providers
For more information on these clinical trials, visit (log-in required): NECS Clinical Trials